ReviewBlood cancer journal2018
Chronic lymphocytic leukemia treatment algorithm 2018.
Review in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Pooled it
- Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription.Haematologica · 2020Trial
- Candidate miRNA Regulators of Blood Transcriptional Signatures for Differential Diagnosis of Chronic Lymphocytic Leukemia and Multiple Myeloma: A Comprehensive In Silico Study.Current issues in molecular biology · 2026Article
- Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data.Journal of managed care & specialty pharmacy · 2026Article
- Spontaneous Tumor Lysis Syndrome as the Initial Presentation of Chronic Lymphocytic Leukemia: A Case Report.Clinical medicine insights. Case reports · 2026Article
- Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.Stem cell research & therapy · 2025Review
- Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- Dual roles of extracellular vesicles in acute lymphoblastic leukemia: implications for disease progression and theranostic strategies.Medical oncology (Northwood, London, England) · 2024Review
- The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab.Cancers · 2024Article
- Association of Cytogenetics Aberrations andGlobal medical genetics · 2024Article
- Synthesis and Pro-Apoptotic Effects of Nitrovinylanthracenes and Related Compounds in Chronic Lymphocytic Leukaemia (CLL) and Burkitt's Lymphoma (BL).Molecules (Basel, Switzerland) · 2023Article
- Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.Current oncology (Toronto, Ont.) · 2023Article
- Secondary involvement of gallbladder by acute lymphoblastic leukemia presenting clinically as cholecystitis in a young patient: a case report.World journal of surgical oncology · 2023Article
- Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.British journal of haematology · 2022Article
- Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model.Journal of experimental & clinical cancer research : CR · 2022Article
- Natural Killer Cell-Mediated Immunotherapy for Leukemia.Cancers · 2022Review
- Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis ofFrontiers in oncology · 2022Article
- Ibrutinib-induced acute kidney injury via interstitial nephritis.Renal failure · 2021Article
- Review
- Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).Annals of hematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as ibrutinib, idelalisib, and venetoclax), and next-generation anti-CD20 monoclonal antibodies (such as obinutuzumab). These agents lead to improved outcomes in CLL, even among patients with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes. Each of these treatments is associated with a unique toxicity profile; in the absence of randomized data, the choice of one type of treatment over another depends on the co-morbidities of the patient. Chemoimmunotherapy still plays an important role in the management of previously untreated CLL patients, particularly among young fit patients who have standard risk FISH profile and mutated IGHV genes. Richter's transformation of CLL remains a difficult complication to treat, although therapy with programmed death 1 inhibitors such as pembrolizumab and nivolumab has shown impressive responses in a subset of patients. Our ability to risk stratify CLL patients continues to evolve; the CLL-International Prognostic Index (CLL-IPI) is the best validated tool in predicting time to first therapy among previously untreated patients. This review summarizes the current approach to risk stratification and management of CLL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.